🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for AMD - Age-Related Macular Degeneration

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD) NCT07502664n/a1 site📍 Irvine Ray Therapeutics, Inc. QA108 Phase III Study in Subjects With Intermediate AMD NCT07189169Phase 31 site📍 Beijing Smilebiotek Zhuhai Limited · Tests: QA108 granules, QA108 granules placebo Blepharoptosis After Repeated Intravitreal Anti-VEGF Injections: A Prospective Study NCT07821450n/a1 site📍 Istanbul Abdulkadir Küçük · Tests: Repeated intravitreal anti-VEGF injection with eyelid speculum Progression Suppression and Retinal Regression in VEGF-resistant AMD NCT07005323NA3 sites📍 Nagoya📍 Amagasaki📍 Ube PharmaBio Corporation · Tests: Pars plana vitrectomy AVIGA3 (Cohort 2.0) NCT07255859NA1 site📍 Singapore Tan Tock Seng Hospital · Tests: Amsler Grid, AVIGA High Resolution Imaging OCT Study NCT07338461NA1 site📍 Milan Heidelberg Engineering GmbH · Tests: Autofluorescence Imaging, Infrared reflectance imaging, OCT imaging, OCTA imaging Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD) NCT05803785Phase 12 sites📍 Sydney📍 Sydney Benobio Co., Ltd. · Tests: BBC1501 Effect of Video Viewing on Intravitreal Injection Experience NCT07002372NA1 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Procedure video viewing A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD NCT06346600n/a10 sites📍 Boston📍 Katy📍 Norfolk Skyline Therapeutics · Tests: SKG0106 Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration NCT04339764Phase 1, Phase 22 sites📍 Baltimore📍 Bethesda National Eye Institute (NEI) · Tests: iPSC-derived RPE/PLGA transplantation The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population NCT06755372n/a1 site📍 Al Fayyum Ain Shams University Real-world Study of Aflibercept 8 mg in nAMD NCT07640997n/a27 sites📍 Beijing📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Aflibercept 8mg Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting NCT05093374Phase 41 site📍 Vienna Medical University of Vienna · Tests: anti-VEGF agent, anti-VEGF agent Ethical Issues of Using Gene Therapy in the Treatment of AMD NCT07004361n/a1 site📍 Nantes Nantes University Hospital Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration NCT07064759Phase 3126 sites📍 Scottsdale📍 Sun City📍 Tucson 4D Molecular Therapeutics · Tests: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice NCT07015034NA2 sites📍 Copenhagen📍 Køge University of Copenhagen · Tests: focus on vision impairment in older patients in general practice Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration NCT07587515Phase 1, Phase 27 sites📍 Beverly Hills📍 Modesto📍 Wake Forest Eyconis INC. · Tests: EYC-0305 A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio NCT07215390Phase 278 sites📍 Gilbert📍 Mesa📍 Phoenix Apellis Pharmaceuticals, Inc. · Tests: APL-3007, pegcetacoplan (APL-2), APL-3007, pegcetacoplan (APL-2), Placebo, Syfovre DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information. NCT07308639n/a1 site📍 Leverkusen Bayer · Tests: anti-VEGF medication Visual Remapping to Aid Reading With Field Loss NCT03848663NA1 site📍 Minneapolis University of Minnesota · Tests: Traditional Remapping, Personalized Remapping Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression NCT04739319n/a1 site📍 East Melbourne Center for Eye Research Australia · Tests: N/A Observational study Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration NCT07367282Phase 45 sites📍 Seongnam📍 Seoul📍 Seoul Junyeop Lee · Tests: Faricimab Injection [Vabysmo] Gene Therapy(FT-003) for Wet AMD NCT06492863Phase 1, Phase 21 site📍 Tianjin Frontera Therapeutics · Tests: FT-003 Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages NCT07427160n/a1 site📍 Trento Marco Mazzola A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO NCT07205887Phase 255 sites📍 Scottsdale📍 Scottsdale📍 Glendale EyeBiotech Ltd. · Tests: Remigromig, Aflibercept 2.0 mg (CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000 NCT07680244NA6 sites📍 Tucson📍 Mountain View📍 San Francisco Carl Zeiss Meditec-Dublin CoCe · Tests: PathFinder 1.0 on CIRRUS HD-OCT Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD NCT07770828Phase 33 sites📍 Phoenix📍 Erie📍 McAllen Ocugen · Tests: OCU410 Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD. NCT06271330n/a1 site📍 Nantes Nantes University Hospital · Tests: Faricimab A Study in Adults With Geographic Atrophy NCT07606365Phase 256 sites📍 Bakersfield📍 Beverly Hills📍 Aurora Sitala Bio LTD · Tests: STL303, Placebo Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals NCT06875245Phase 41 site📍 Prague Faculty Hospital Kralovske Vinohrady · Tests: Faricimab Injection
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy